EVOK — Evoke Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $3.85m
- -$4.75m
- $10.25m
Annual cashflow statement for Evoke Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.2 | -8.54 | -8.22 | -7.79 | -5.35 |
| Non-Cash Items | 1.63 | 1.8 | 1.5 | 1.26 | 0.786 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.9 | -5.62 | 0.132 | 1.55 | -0.892 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -6.63 | -12.4 | -6.6 | -4.98 | -5.46 |
| Financing Cash Flow Items | — | — | -0.149 | -0.119 | -0.426 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.04 | 13.4 | 7.29 | -0.119 | 14.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.41 | 1.08 | 0.699 | -5.1 | 8.86 |